In light of the amendments made in the Regulation on the Procedures and Principles Regarding the Monitoring of Transactions Affecting Foreign Exchange Positions by the Central Bank of the Republic of Türkiye (“Regulation”)on 3 May 2025, the criteria for companies subject to reporting obligations have been revised along with the reporting periods. This development has created a need to re-evaluate the reporting obligation, its scope and other practical issues relating to the…
»
With the decision of the Personal Data Protection Board dated 04.09.2025 and numbered 2025/1572, which entered into force by being published in the Official Gazette on 01.10.2025, the scope of data controllers exempt from the obligation to register with the Data Controllers’ Registry (VERBİS) has been amended.
Previously, data controllers whose main activity involved processing special categories of personal data were subject to the VERBİS registration obligation. However…
»
The Law No. 7557 on the “Amendments to Certain Laws Related to Health and to the Decree Law No. 663”, which entered into force on 24 July 2025, introduced numerous changes that directly affect the healthcare sector. One of these changes is the Additional Article 20, which was added to the Basic Law on Health Services. This article aims to address critical areas such as the placement of counterfeit medical devices on the market, unauthorized sales and technical service…
»
On 2 July 2025, the Enlarged Board of Appeal of the European Patent Office (“EPO”), in its decision G 1/23, clarified whether a product already placed on the market, but whose internal structure cannot be analysed or reproduced by the skilled person, may nevertheless be excluded from the state of the art in the assessment of inventive step. In doing so, the Board added a new dimension to the ongoing debate following decision G 1/92.
The dispute giving rise to the decision…
»
Before filing lawsuits to assert patent rights against generics or biosimilars, the patent holder essentially operates in the dark. This is because, particularly in cases where the summary of product characteristics (“SmPC”) of the biosimilar/generic drug has not yet been published, or when it is not clear from the limited information in the SmPC whether the patent has been infringed, the relevant sections of the biosimilar/generic product's dossier must be examined to assess…
»
According to the Trademark Examination Guideline of the Turkish Patent and Trademark Office, which is aligned with the European Union Intellectual Property Office (EUIPO) guidelines, the comparison of trademarks should be based on the overall impression created by the marks. In this assessment, the length of a trademark can be an important factor. In general, the shorter a sign is, the easier it is for the public to perceive each of its elements. Conversely, in longer signs…
»
